Vivek Subbiah: We need to challenge Standard-of-care Paradigms in the Precision Oncology era
Vivek Subbiah shared a post on LinkedIn:
“Such a delight to deliver a lecture and join an amazing panel discussion on Rare Cancer, Precision Medicine and how do we offer cutting edge personalized treatments and clinical trials for all patients with rare cancers everywhere.
“2024 Rare Cancer Symposium, Indianapolis, IN”
The time is now. We need to challenge Standard-of-care Paradigms in the Precision Oncology era.
Together we can all Eradicate Cancer
Thanks to Dr. Sumeet Bhatia and Dr. Ruemu Birhiray for the invite & organizing the meeting.
Incredible speaker line up .
Read about this idea in our paper published at Cell Press journal Trends in Cancer.”
Challenging Standard-of-Care Paradigms in the Precision Oncology Era
Authors:
Source: Vivek Subbiah/LinkedIn
Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023